Figure 1.
Altered airway function in the early asthmatic response. All groups were exposed to secondary challenge with 5% ovalbumin (OVA), and changes in lung resistance (RL) were monitored. Administration of the BLT1 antagonist was as described in Materials and Methods. n = 12 in each group. Means ± SEM are shown. *P < 0.05. PBS/OVA/vehicle PBS/OVA/antagonist versus OVA/OVA/vehicle OVA/OVA/antagonist. PBS/OVA = nonsensitized and challenged. OVA/Saline = sensitized and challenged and secondary challenged with saline. OVA/OVA = sensitized and challenged.